Arginylglycylaspartic Acid-Surface-Functionalized Doxorubicin-Loaded Lipid-Core nanocapsules as a strategy to target Alpha(V) Beta(3) integrin expressed on tumor cells

Detalhes bibliográficos
Autor(a) principal: Antonow, Michelli Barcelos
Data de Publicação: 2018
Outros Autores: Franco, Camila, Prado, Willian Andrade, Beckenkamp, Aline, Silveira, Gustavo Pozza, Buffon, Andreia, Guterres, Silvia Stanisçuaski, Pohlmann, Adriana Raffin
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFRGS
Texto Completo: http://hdl.handle.net/10183/182662
Resumo: Doxorubicin (Dox) clinical use is limited by dose-related cardiomyopathy, becoming more prevalent with increasing cumulative doses. Previously, we developed Dox-loaded lipid-core nanocapsules (Dox-LNC) and, in this study, we hypothesized that self-assembling and interfacial reactions could be used to obtain arginylglycylaspartic acid (RGD)-surface-functionalized-Dox-LNC, which could target tumoral cells overexpressing v 3 integrin. Human breast adenocarcinoma cell line (MCF-7) and human glioblastoma astrocytoma (U87MG) expressing different levels of v 3 integrin were studied. RGD-functionalized Dox-LNC were prepared with Dox at 100 and 500 mg mL1 (RGD-MCMN (Dox100) and RGD-MCMN (Dox500)). Blank formulation (RGD-MCMN) had z-average diameter of 162 6 nm, polydispersity index of 0.11 0.04, zeta potential of +13.2 1.9 mV and (6.2 1.1) 1011 particles mL1, while RGD-MCMN (Dox100) and RGD-MCMN (Dox500) showed respectively 146 20 and 215 25 nm, 0.10 0.01 and 0.09 0.03, +13.8 2.3 and +16.4 1.5 mV and (6.9 0.6) 1011 and (6.1 1.0) 1011 particles mL1. RGD complexation was 7.73 104 molecules per nanocapsule and Dox loading were 1.51 104 and 7.64 104 molecules per nanocapsule, respectively. RGD-functionalized nanocapsules had an improved uptake capacity by U87MG cells. Pareto chart showed that the cell viability was mainly affected by the Dox concentration and the period of treatment in both MCF-7 and U87MG. The influence of RGD-functionalization on cell viability was a determinant factor exclusively to U87MG.
id UFRGS-2_c123524838131ff2f666fada9f2efea5
oai_identifier_str oai:www.lume.ufrgs.br:10183/182662
network_acronym_str UFRGS-2
network_name_str Repositório Institucional da UFRGS
repository_id_str
spelling Antonow, Michelli BarcelosFranco, CamilaPrado, Willian AndradeBeckenkamp, AlineSilveira, Gustavo PozzaBuffon, AndreiaGuterres, Silvia StanisçuaskiPohlmann, Adriana Raffin2018-09-26T02:33:35Z20182079-4991http://hdl.handle.net/10183/182662001076172Doxorubicin (Dox) clinical use is limited by dose-related cardiomyopathy, becoming more prevalent with increasing cumulative doses. Previously, we developed Dox-loaded lipid-core nanocapsules (Dox-LNC) and, in this study, we hypothesized that self-assembling and interfacial reactions could be used to obtain arginylglycylaspartic acid (RGD)-surface-functionalized-Dox-LNC, which could target tumoral cells overexpressing v 3 integrin. Human breast adenocarcinoma cell line (MCF-7) and human glioblastoma astrocytoma (U87MG) expressing different levels of v 3 integrin were studied. RGD-functionalized Dox-LNC were prepared with Dox at 100 and 500 mg mL1 (RGD-MCMN (Dox100) and RGD-MCMN (Dox500)). Blank formulation (RGD-MCMN) had z-average diameter of 162 6 nm, polydispersity index of 0.11 0.04, zeta potential of +13.2 1.9 mV and (6.2 1.1) 1011 particles mL1, while RGD-MCMN (Dox100) and RGD-MCMN (Dox500) showed respectively 146 20 and 215 25 nm, 0.10 0.01 and 0.09 0.03, +13.8 2.3 and +16.4 1.5 mV and (6.9 0.6) 1011 and (6.1 1.0) 1011 particles mL1. RGD complexation was 7.73 104 molecules per nanocapsule and Dox loading were 1.51 104 and 7.64 104 molecules per nanocapsule, respectively. RGD-functionalized nanocapsules had an improved uptake capacity by U87MG cells. Pareto chart showed that the cell viability was mainly affected by the Dox concentration and the period of treatment in both MCF-7 and U87MG. The influence of RGD-functionalization on cell viability was a determinant factor exclusively to U87MG.application/pdfengNanomaterials. Suíça. Vol. 8, no. 1 (2018), p. 1-18Nanocápsulas de núcleo lipídicoCâncerDoxorrubicinaLipid-core nanocapsulesCancerRGDDoxorubicinActive drug targetingSurface-functionalizationArginylglycylaspartic Acid-Surface-Functionalized Doxorubicin-Loaded Lipid-Core nanocapsules as a strategy to target Alpha(V) Beta(3) integrin expressed on tumor cellsEstrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSORIGINAL001076172.pdfTexto completo (inglês)application/pdf3057755http://www.lume.ufrgs.br/bitstream/10183/182662/1/001076172.pdf7567c3765ac47801fafec85960db69e1MD51TEXT001076172.pdf.txt001076172.pdf.txtExtracted Texttext/plain63642http://www.lume.ufrgs.br/bitstream/10183/182662/2/001076172.pdf.txt73ef65602bf2ad488521b51143392696MD52THUMBNAIL001076172.pdf.jpg001076172.pdf.jpgGenerated Thumbnailimage/jpeg1833http://www.lume.ufrgs.br/bitstream/10183/182662/3/001076172.pdf.jpg5e2f0ea000dc144a0c9ca31062741f78MD5310183/1826622018-10-05 07:58:38.833oai:www.lume.ufrgs.br:10183/182662Repositório InstitucionalPUBhttps://lume.ufrgs.br/oai/requestlume@ufrgs.bropendoar:2018-10-05T10:58:38Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false
dc.title.pt_BR.fl_str_mv Arginylglycylaspartic Acid-Surface-Functionalized Doxorubicin-Loaded Lipid-Core nanocapsules as a strategy to target Alpha(V) Beta(3) integrin expressed on tumor cells
title Arginylglycylaspartic Acid-Surface-Functionalized Doxorubicin-Loaded Lipid-Core nanocapsules as a strategy to target Alpha(V) Beta(3) integrin expressed on tumor cells
spellingShingle Arginylglycylaspartic Acid-Surface-Functionalized Doxorubicin-Loaded Lipid-Core nanocapsules as a strategy to target Alpha(V) Beta(3) integrin expressed on tumor cells
Antonow, Michelli Barcelos
Nanocápsulas de núcleo lipídico
Câncer
Doxorrubicina
Lipid-core nanocapsules
Cancer
RGD
Doxorubicin
Active drug targeting
Surface-functionalization
title_short Arginylglycylaspartic Acid-Surface-Functionalized Doxorubicin-Loaded Lipid-Core nanocapsules as a strategy to target Alpha(V) Beta(3) integrin expressed on tumor cells
title_full Arginylglycylaspartic Acid-Surface-Functionalized Doxorubicin-Loaded Lipid-Core nanocapsules as a strategy to target Alpha(V) Beta(3) integrin expressed on tumor cells
title_fullStr Arginylglycylaspartic Acid-Surface-Functionalized Doxorubicin-Loaded Lipid-Core nanocapsules as a strategy to target Alpha(V) Beta(3) integrin expressed on tumor cells
title_full_unstemmed Arginylglycylaspartic Acid-Surface-Functionalized Doxorubicin-Loaded Lipid-Core nanocapsules as a strategy to target Alpha(V) Beta(3) integrin expressed on tumor cells
title_sort Arginylglycylaspartic Acid-Surface-Functionalized Doxorubicin-Loaded Lipid-Core nanocapsules as a strategy to target Alpha(V) Beta(3) integrin expressed on tumor cells
author Antonow, Michelli Barcelos
author_facet Antonow, Michelli Barcelos
Franco, Camila
Prado, Willian Andrade
Beckenkamp, Aline
Silveira, Gustavo Pozza
Buffon, Andreia
Guterres, Silvia Stanisçuaski
Pohlmann, Adriana Raffin
author_role author
author2 Franco, Camila
Prado, Willian Andrade
Beckenkamp, Aline
Silveira, Gustavo Pozza
Buffon, Andreia
Guterres, Silvia Stanisçuaski
Pohlmann, Adriana Raffin
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Antonow, Michelli Barcelos
Franco, Camila
Prado, Willian Andrade
Beckenkamp, Aline
Silveira, Gustavo Pozza
Buffon, Andreia
Guterres, Silvia Stanisçuaski
Pohlmann, Adriana Raffin
dc.subject.por.fl_str_mv Nanocápsulas de núcleo lipídico
Câncer
Doxorrubicina
topic Nanocápsulas de núcleo lipídico
Câncer
Doxorrubicina
Lipid-core nanocapsules
Cancer
RGD
Doxorubicin
Active drug targeting
Surface-functionalization
dc.subject.eng.fl_str_mv Lipid-core nanocapsules
Cancer
RGD
Doxorubicin
Active drug targeting
Surface-functionalization
description Doxorubicin (Dox) clinical use is limited by dose-related cardiomyopathy, becoming more prevalent with increasing cumulative doses. Previously, we developed Dox-loaded lipid-core nanocapsules (Dox-LNC) and, in this study, we hypothesized that self-assembling and interfacial reactions could be used to obtain arginylglycylaspartic acid (RGD)-surface-functionalized-Dox-LNC, which could target tumoral cells overexpressing v 3 integrin. Human breast adenocarcinoma cell line (MCF-7) and human glioblastoma astrocytoma (U87MG) expressing different levels of v 3 integrin were studied. RGD-functionalized Dox-LNC were prepared with Dox at 100 and 500 mg mL1 (RGD-MCMN (Dox100) and RGD-MCMN (Dox500)). Blank formulation (RGD-MCMN) had z-average diameter of 162 6 nm, polydispersity index of 0.11 0.04, zeta potential of +13.2 1.9 mV and (6.2 1.1) 1011 particles mL1, while RGD-MCMN (Dox100) and RGD-MCMN (Dox500) showed respectively 146 20 and 215 25 nm, 0.10 0.01 and 0.09 0.03, +13.8 2.3 and +16.4 1.5 mV and (6.9 0.6) 1011 and (6.1 1.0) 1011 particles mL1. RGD complexation was 7.73 104 molecules per nanocapsule and Dox loading were 1.51 104 and 7.64 104 molecules per nanocapsule, respectively. RGD-functionalized nanocapsules had an improved uptake capacity by U87MG cells. Pareto chart showed that the cell viability was mainly affected by the Dox concentration and the period of treatment in both MCF-7 and U87MG. The influence of RGD-functionalization on cell viability was a determinant factor exclusively to U87MG.
publishDate 2018
dc.date.accessioned.fl_str_mv 2018-09-26T02:33:35Z
dc.date.issued.fl_str_mv 2018
dc.type.driver.fl_str_mv Estrangeiro
info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10183/182662
dc.identifier.issn.pt_BR.fl_str_mv 2079-4991
dc.identifier.nrb.pt_BR.fl_str_mv 001076172
identifier_str_mv 2079-4991
001076172
url http://hdl.handle.net/10183/182662
dc.language.iso.fl_str_mv eng
language eng
dc.relation.ispartof.pt_BR.fl_str_mv Nanomaterials. Suíça. Vol. 8, no. 1 (2018), p. 1-18
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFRGS
instname:Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
instname_str Universidade Federal do Rio Grande do Sul (UFRGS)
instacron_str UFRGS
institution UFRGS
reponame_str Repositório Institucional da UFRGS
collection Repositório Institucional da UFRGS
bitstream.url.fl_str_mv http://www.lume.ufrgs.br/bitstream/10183/182662/1/001076172.pdf
http://www.lume.ufrgs.br/bitstream/10183/182662/2/001076172.pdf.txt
http://www.lume.ufrgs.br/bitstream/10183/182662/3/001076172.pdf.jpg
bitstream.checksum.fl_str_mv 7567c3765ac47801fafec85960db69e1
73ef65602bf2ad488521b51143392696
5e2f0ea000dc144a0c9ca31062741f78
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)
repository.mail.fl_str_mv lume@ufrgs.br
_version_ 1817725032176025600